How does ICE Bioscience reduce IP and know-how risks when sponsors transfer proprietary compounds and assay designs?

ICE Bioscience builds discovery campaigns on internal platform technologies, including ICESTP Safety Panels and ICECP and KRAS cancer cell panels, which reduces the need for sponsors to transfer proprietary assay architectures or cell assets. ICESTP uses predefined target sets aligned with Bowes-44 and Safety-77 literature, and ICECP uses an internal bank of more than 600 tumor cell lines, over 100 engineered and resistant lines, and more than 500 human tumor cell lines for panel construction.

How does ICE Bioscience address assay reproducibility and false-positive or false-negative risk?

ICESTP Safety Panels 44 and 77 are functional secondary pharmacology panels run in both single-concentration and full dose–response modes with potency estimation. All kinase targets are profiled at 1 mM ATP, and reports include radar plots and concentration–effect curves, allowing sponsors to evaluate consistency and confirm pharmacology across targets.

How does ICE Bioscience support raw data transparency and secondary pharmacology data integrity?

ICESTP outputs include full dose–response data, numerical effect tables, and graphical plots for each target, giving sponsors visibility from primary response values through to IC50 or EC50 metrics. The panels are aligned with published Bowes-44 and Safety-77 recommendations, which provide an external reference for target selection and data structure.

How does ICE Bioscience limit variability in high-throughput screening compared with manual offshore setups?

ICE Bioscience operates a joint automated laboratory with SPT Labtech in Beijing that integrates firefly liquid handling into high-throughput screening and assay development workflows. Firefly supports non-contact positive displacement dispensing over nanoliter to milliliter ranges in 96-well and 384-well formats and is used for 2D and 3D viability, clonogenic, and panel assays, reducing operator and plate-to-plate variability.

How does ICE Bioscience align safety pharmacology services with Western regulatory expectations?

ICESTP Safety Panel 44 is described as aligned with historical Bowes-44 off-target selection and ICH expectations, and ICESTP Safety Panel 77 is described as aligned with the industry Safety-77 framework for secondary pharmacology. The ICESTP Drug Abuse Safety Panel follows FDA recommendations for assessing drug abuse potential with 55 CNS targets and 101 assays.

RIPTAC Discovery Services - RIPTAC

RIPTAC Discovery Services

Induced Proximity Discovery

Integrated support for RIPTAC discovery, from ternary-complex modeling to biochemical, biophysical and cellular validation.

What is RIPTAC?

RIPTACs, or Regulated Induced Proximity Targeting Chimeras, are bifunctional molecules designed to bring a tumor-selective target protein into proximity with a pan-essential protein. In target-positive cells, this induced proximity can disrupt essential protein function and drive selective cancer cell killing, while sparing healthy cells with low or absent target expression.

As an emerging induced proximity modality, RIPTAC discovery requires more than routine assay execution. Productive programs depend on ternary-complex hypothesis generation, structure-informed design, orthogonal validation and biologically meaningful downstream readouts.

ICE Bioscience provides a connected workflow to help advance RIPTAC programs with greater confidence. Our platform combines in silico design, orthogonal assay development, target engagement analysis and downstream functional evaluation to support faster and more informed decision-making.

Ternary-Complex Modeling

Structure-guided RIPTAC design supported by docking, pose comparison and molecular dynamics analysis.

We help prioritize productive ternary-complex hypotheses and identify candidate molecules for downstream testing.

Orthogonal Validation

Biophysical and biochemical assays to characterize binary binding, ternary-complex formation and mechanism-related activity.

Available assay formats include HTRF, TR-FRET, SPR and spectral shift.

Cellular & Preclinical Support

Cell-based target engagement and functional readouts help connect ternary-complex biology to pharmacological outcome.

We further support RIPTAC programs with safety panels, in vitro ADME, PK/PD and selected in vivo studies.

Why ICE Bioscience for RIPTAC discovery?

Beyond standard assay execution, we integrate modeling with experimental validation to support mechanism-driven RIPTAC discovery.

This connected workflow helps reduce uncertainty, accelerate candidate prioritization and generate decision-ready data across discovery stages.

Service Scope

Docking & MD

Ternary Complex Formation Assays

Biophysics

Target Engagement

Reporter & Functional Assays

Safety Panels

In Vitro ADME

PK/PD Support

In Vivo Studies

Let’s discuss your RIPTAC program

Looking for a partner to support RIPTAC discovery from modeling through validation and translational studies? Our team can help build a tailored workflow around your program needs.

Target Based Assays

Cell Based Assays

Featured Services

In Vitro Safety Assessment

In Vitro Immunology Assays

In Vivo Pharmacology

DMPK

Service Portfolio